芪丹颗粒剂治疗肺间质纤维化105例临床研究  

Clinical Study on Qidan Granule for Treatment of 105 Cases of Pulmonary Interstitial Fibrosis

作　　者：靳长俊[1] 辛洪涛[1] 林殿杰[1] 高桂新[1] 张华楠[1] 王贞 

机构地区：[1]山东大学山东省立医院呼吸内科 [2]山东省乐陵市人民医院

出　　处：《中医杂志》2005年第8期595-597,共3页Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金(30271625)

摘　　要：目的:观察芪丹颗粒剂对肺间质纤维化患者的临床疗效。方法:选择105例肺间质纤维化患者作为治疗组,给予芪丹颗粒剂,对照组60例,给予强的松0.5mg/kg.两组疗程均为3～6个月,每1～3个月随诊1次。观察两组患者治疗后的症状、体征、肺部高分辨率 CT(HRCT)及肺功能变化。结果:治疗6个月后,治疗组症状、体征改善率优于对照组(P<0.05或 P<0.01);治疗组治疗3个月和6个月后,肺 HRCT 和肺功能改善率优于对照组(P<0.05或 P<0.01)。结论:芪丹颗粒剂可以不同程度地改善肺间质纤维化患者症状和体征,使患者肺功能停止恶化,且用药期间未见任何副作用,耐受性良好。Objective： To investigate clinical therapeutic effect of Qidan Granule on pulmonary interstitial fibrosis （PIF）. Methods： The treatment group （105 cases） were treated by Qidan Granule, 3 times a day, and the control group （60 cases） were treated by prednisone, 0. 5mg/kg,for 3-6 months. The patients were followed up once every 1-3 months. Changes of symptoms, signs and high-resolution computed tomogram（HRCT） and pulmonary function were investigated after treatment. Results：After treatment of 6 months,the improvement rate of symptoms and signs in the treatment group was superior to that in the control group（P〈0. 05 or P〈0. 01） ;After treatment for 3 or 6 months,the improvement rates of HRCT and the pulmonary function in the treatment group were better than those in the control group（P〈0. 05 or P〈0. 01）. Conclusion ：Qidan Granule can improve symptoms and signs of the patient with pulmonary interstitial fibrosis in varying degrees and stop exacerbation of pulmonary function with no adverse effect.

关 键 词：芪丹颗粒剂 肺间质纤维化 中药制剂 肺功能 病理学检查 

分 类 号：R259[医药卫生—中西医结合]